Feeds:
Posts
Comments

Archive for August, 2009

NZ HERALD: Otago University biomedical researchers have been awarded a $950,000 Health Research Council Grant for a three-year project to investigate the likely role of a protein, activin C, in promoting prostate cancer growth. READ MORE>

Read Full Post »

NZ HERALD: He’s a doctor who has written a book on prostate cancer, he’s built a wellness retreat at Abel Tasman National Park and his hobbies include nutrition. READ MORE>

Read Full Post »

YAHOO XTRA NEWS: Researchers searching for a cure for obesity have developed a drug that not only makes mice lose weight, but reverses diabetes, lowers their cholesterol, has effects on prostate cancer cells – something that may help explain links between prostate cancer and obesity. READ MORE>

Read Full Post »

NZ DOCTOR:  Restrictions on access to intravenous prostate cancer treatment drug Zoladex (goserelin) will be lifted tomorrow in an agreement that sees Pharmac continuing to fully subsidise the drug. As part of the same agreement with manufacturer AstraZeneca, a special authority will no longer be required for  the drug, which will have subsidy and delisting protection until June 30, 2013. READ MORE>

Read Full Post »

PROSTABLOG NZ: Canned food giant Wattie’s is doing its bit to support the NZ Prostate Cancer Foundation’s Blue September campaign by donating 5c a can from every sale of Wattie’s canned tomato sauce and Wattie’s canned tomato products featuring the Blue September label. READ MORE>

watties

Read Full Post »

SUNDAY HERALD (SCOTLAND): Suspicions are growing about the prostate cancer medical evidence used to justify the release of the man convicted of the Lockerbie bombing. READ MORE>

Read Full Post »

PROSTABLOG NZ: Blue September – the Prostate Cancer Foundation of NZ’s annual awareness campaign – has started already. CLICK HERE>

Read Full Post »

SHAKOPEE VALLEY NEWS: A $2 million, 16-wheel mobile unit with leather seats, computers, flat-screen televisions and state-of-the-art medical technology is being used to bring medical testing to American Indian populations in Minnesota. READ MORE>

Read Full Post »

PSA RISING.COM: A potential anti-cancer agent called ZD4054 is being tested in clinical trials around the world in patients with prostate cancer to see if it can block the uptake of endothelin A and thereby shrink tumors or slow their progression. READ MORE>

Read Full Post »

URO TODAY: Degarelix, a recently approved LHRH antagonist, has been shown to work more quickly in lowering serum testosterone levels, with acceptable safety and a mechanism that avoids the testosterone surges associated with LHRH agonist use. READ MORE>

Read Full Post »

Older Posts »